Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
November 4, 2015 Management to host conference call today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial ...
October 27, 2015 Conference call scheduled for November 4, 2015 at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will ...
October 15, 2015 -Eleven Granted Isunakinra as the International Nonproprietary Name for EBI-005- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, ...
September 1, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to...
August 31, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, PhD, President and Chief Executive Officer, will present a company ...
August 13, 2015 Management to host conference call today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial ...
August 12, 2015 - Top-line Data Expected in First Quarter 2016 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced dose administrat...
August 4, 2015 Conference call scheduled for August 13, 2015 at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will ...
June 24, 2015 - Chief Financial Officer Gregory Perry Resigns - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Gregory D....
May 18, 2015 - Study Did Not Achieve Primary Endpoints; No Statistical Difference between EBI-005 and Vehicle Control - - EBI-005 Program to Focus on Allergic Conjunctivitis with Pivotal Phase 3 Study to Initiate in Second Half of 2015 - - Conference Call Scheduled for 8:30 a.m. ET Today - ...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
2.25
Change:
0.00
Day High:
N/A
Day Low:
N/A
Volume:
N/A
4:00 PM ET on March 28, 2017
Delayed at least 20 minutes.